US-based biotechnology firm Ignyta has entered into a license agreement with Nerviano Medical Sciences (Nerviano), under which Ignyta will get exclusive global development and marketing rights of tyrosine kinase inhibitors RXDX-101 and RXDX-102.
RXDX-101 is directed to the TrkA, ROS1 and ALK proteins, which is in a Phase I/II clinical trial in molecularly defined patient populations for the treatment of solid tumors.
RXDX-102, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors, TrkA, TrkB and TrkC, which is currently in preclinical development for the treatment of multiple cancers.
Under the deal, which will become effective upon Ignyta's completion of an equity or debt financing resulting in proceeds of at least $20m, Ignyta will assume sole responsibility for global development and commercialization of both the tyrosine kinase inhibitors.
Nerviano, which is a former Pfizer/Pharmacia oncology discovery facility in Italy, will be entitled to receive certain upfront and milestone payments, as well as tiered royalty payments on future net sales of RXDX-101 or RXDX-102.
